200 related articles for article (PubMed ID: 7967705)
41. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
42. Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
Mei C; Ren Y; Zhou X; Ye L; Ma L; Luo Y; Lin P; Xu W; Lu C; Yang H; Yu W; Mao L; Wei J; Jin J; Tong H
Leuk Lymphoma; 2019 May; 60(5):1136-1145. PubMed ID: 30301399
[TBL] [Abstract][Full Text] [Related]
43. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
Fenaux P; Morel P; Rose C; Lai JL; Jouet JP; Bauters F
Br J Haematol; 1991 Apr; 77(4):497-501. PubMed ID: 2025575
[TBL] [Abstract][Full Text] [Related]
44. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
45. Cytogenetic clonality analysis: typical patterns in myelodysplastic syndrome and acute myeloid leukaemia.
van Lom K; Hagemeijer A; Vandekerckhove F; Smit EM; Löwenberg B
Br J Haematol; 1996 Jun; 93(3):594-600. PubMed ID: 8652379
[TBL] [Abstract][Full Text] [Related]
46. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
Wattel E; Solary E; Hecquet B; Caillot D; Ifrah N; Brion A; Milpied N; Janvier M; Guerci A; Rochant H; Cordonnier C; Dreyfus F; Veil A; Hoang-Ngoc L; Stoppa AM; Gratecos N; Sadoun A; Tilly H; Brice P; Lioure B; Desablens B; Pignon B; Abgrall JP; Leporrier M; Fenaux P
Adv Exp Med Biol; 1999; 457():35-46. PubMed ID: 10500778
[TBL] [Abstract][Full Text] [Related]
47. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
48. Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases.
Iwakiri R; Ohta M; Mikoshiba M; Tsutsumi H; Kumakawa T; Mori M
Int J Hematol; 2002 Jan; 75(1):45-50. PubMed ID: 11843290
[TBL] [Abstract][Full Text] [Related]
49. Significance of trilineage myelodysplasia in de novo acute myeloid leukaemia during remission rather than at diagnosis.
Tamura S; Takemoto Y; Wada H; Itoh T; Mori A; Saheki K; Okada M; Takatsuka H; Fujimori Y; Okamoto T; Kakishita E
Br J Haematol; 1998 Jun; 101(4):743-8. PubMed ID: 9674749
[TBL] [Abstract][Full Text] [Related]
50. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.
Gupta P; Niehans GA; LeRoy SC; Gupta K; Morrison VA; Schultz C; Knapp DJ; Kratzke RA
Leukemia; 1999 Jan; 13(1):44-53. PubMed ID: 10049059
[TBL] [Abstract][Full Text] [Related]
51. Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
Schuler E; Zadrozny N; Blum S; Schroeder T; Strupp C; Hildebrandt B; Kündgen A; Gattermann N; Aul C; Kondakci M; Kobbe G; Haas R; Germing U
Ann Hematol; 2018 Dec; 97(12):2325-2332. PubMed ID: 30078145
[TBL] [Abstract][Full Text] [Related]
52. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
[TBL] [Abstract][Full Text] [Related]
53. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.
Grövdal M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Wallvik J; Tangen JM; Oberg G; Jacobsen SE; Hokland P; Porwit A; Hellström-Lindberg E
Clin Cancer Res; 2007 Dec; 13(23):7107-12. PubMed ID: 18056190
[TBL] [Abstract][Full Text] [Related]
54. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
Hasle H; Kerndrup G; Yssing M; Clausen N; Ostergaard E; Jacobsen N; Jacobsen BB
Leukemia; 1996 Aug; 10(8):1269-73. PubMed ID: 8709630
[TBL] [Abstract][Full Text] [Related]
55. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
56. [Analysis on laboratory and clinical characteristics in 65 cases of myelodysplastic syndrome].
Chen BA; Gao C; Ding J; Ding JH; Sun YY; Zhao G; Cheng J; Wang J; Bao W; Song HH; Xia GH; Ma JL; Wu LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1472-6. PubMed ID: 20030929
[TBL] [Abstract][Full Text] [Related]
57. Differentiation induction in myelodysplasia and acute myeloid leukaemia: use of synergistic drug combinations.
Francis GE; Mufti GJ; Knowles SM; Berney JJ; Guimaraes JE; Secker-Walker LM; Hamblin TJ
Leuk Res; 1987; 11(11):971-7. PubMed ID: 3480401
[TBL] [Abstract][Full Text] [Related]
58. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
59. [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors].
Xu XS; Ding H; Zhang X; Liao Y; Li H; Liu QY; Liu JZ; Zhang L; Huang J; Gong YP; Ma HB; Xiang B; Dai Y; Hou L; Shuai X; Niu T; Wu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):742-748. PubMed ID: 38049318
[No Abstract] [Full Text] [Related]
60. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
